Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Lenalidomide CR by Nanexa for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Lenalidomide CR is under clinical development by Nanexa and currently in Phase I for Multiple Myeloma (Kahler Disease). According to...